TY - JOUR
T1 - Efficacy of capacitive resistive monopolar radiofrequency in the physiotherapeutic treatment of chronic pelvic pain syndrome
T2 - A randomized controlled trial
AU - Carralero-Martínez, Andrea
AU - Muñoz Pérez, Miguel A.
AU - Kauffmann, Stèphanie
AU - Blanco-Ratto, Laia
AU - Ramírez-García, Inés
N1 - Funding Information:
The authors want to thank Dr. Sebastià Sendròs (INDIBA SAU, ES) for partially supporting the equipment (INDIBA, 350 VA, and 100 W, at 448 kHz) to be used for this study; RAPbarcelona Physiotherapy Clinical Center, for contributing to the clinical trial and collecting data; Ms. Helen Poliquin, Ms. Stephanie Lonsdale, and Dr. Emília Sánchez, for their help in reviewing the final version of the manuscript. Partially funded by INDIBA SAU, ES and co-funded by RAPbarcelona, Physiotherapy Clinical Center.
Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/4
Y1 - 2022/4
N2 - Aim: To evaluate the efficacy of adjuvant, capacitive resistive monopolar radiofrequency (CRMRF, INDIBA) treatment at 448 kHz together with physiotherapeutic techniques compared to a sham treatment with the same techniques, for pain reduction and quality of life (QoL) improvements in patients with chronic pelvic pain syndrome (CPPS). Methods: A triple-blind, randomized controlled trial (RCT) including patients with CPPS randomly allocated (1:1) to a CRMRF-activated group (intervention) or a CRMRF-deactivated one (control). Both groups received physiotherapeutic techniques and pain education weekly for 10 consecutive weeks. Data from a visual analogical scale and the SF-12 questionnaire were collected at trial commencement and repeated at the 5th and 10th sessions. Pain intensity was considered the main outcome. For the comparisons between variables, the χ2 and Student's t test were used. Superiority was analyzed by estimating the mean change (95% confidence interval). Analysis was performed for the per-protocol and the intention-to-treat populations. The statistical significance level was set at p < 0.05. Results: Eighty-one patients were included (67.9% women) with a mean age of 43.6 years (SD 12.9). CRMRF lessened pain scores by more than 2 points and improved QoL by 5 points. There were no relevant side effects and overall adherence to the treatment was 86.4%. Conclusions: This is the first RCT that evaluates the efficacy of CRMRF (INDIBA) compared to a sham treatment, and demonstrates its superiority in decreasing pain and improving QoL. Such results may lead to greater prescribing of CRMRF when treating CPPS patients.
AB - Aim: To evaluate the efficacy of adjuvant, capacitive resistive monopolar radiofrequency (CRMRF, INDIBA) treatment at 448 kHz together with physiotherapeutic techniques compared to a sham treatment with the same techniques, for pain reduction and quality of life (QoL) improvements in patients with chronic pelvic pain syndrome (CPPS). Methods: A triple-blind, randomized controlled trial (RCT) including patients with CPPS randomly allocated (1:1) to a CRMRF-activated group (intervention) or a CRMRF-deactivated one (control). Both groups received physiotherapeutic techniques and pain education weekly for 10 consecutive weeks. Data from a visual analogical scale and the SF-12 questionnaire were collected at trial commencement and repeated at the 5th and 10th sessions. Pain intensity was considered the main outcome. For the comparisons between variables, the χ2 and Student's t test were used. Superiority was analyzed by estimating the mean change (95% confidence interval). Analysis was performed for the per-protocol and the intention-to-treat populations. The statistical significance level was set at p < 0.05. Results: Eighty-one patients were included (67.9% women) with a mean age of 43.6 years (SD 12.9). CRMRF lessened pain scores by more than 2 points and improved QoL by 5 points. There were no relevant side effects and overall adherence to the treatment was 86.4%. Conclusions: This is the first RCT that evaluates the efficacy of CRMRF (INDIBA) compared to a sham treatment, and demonstrates its superiority in decreasing pain and improving QoL. Such results may lead to greater prescribing of CRMRF when treating CPPS patients.
KW - INDIBA
KW - bladder pain syndrome
KW - capacitive resistive monopolar radiofrequency
KW - chronic pelvic pain
KW - genital pain
KW - pain
KW - quality of life
KW - randomized controlled trial
KW - therapeutic interventions
UR - http://www.scopus.com/inward/record.url?scp=85126028142&partnerID=8YFLogxK
U2 - 10.1002/nau.24903
DO - 10.1002/nau.24903
M3 - Article
C2 - 35266184
AN - SCOPUS:85126028142
SN - 0733-2467
VL - 41
SP - 962
EP - 972
JO - Neurourology and Urodynamics
JF - Neurourology and Urodynamics
IS - 4
ER -